XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
Acquiring Company
XOMA Royalty Corporation
Acquired Company
DSUVIA
BerkeleyEmeryvilleBiotechnologyHealth CareBiotechnologyPharmaceuticalDescription
XOMA Corporation has expanded its commercial royalty and milestone portfolio with the acquisition of an economic interest in DSUVIA® (sufentanil sublingual tablet) from Talphera, Inc. The acquisition includes the right to receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S. Department of Defense purchases, as well as entitlement to no less than 50% of the potential $116.5 million in milestone payments.
Quick answer
XOMA Royalty Corporation is acquiring DSUVIA, announced January 18, 2024. XOMA Royalty Corporation is based in Berkeley, California, United States.
- How much did XOMA Royalty Corporation pay for DSUVIA?
- The deal value was not disclosed.
- What does XOMA Royalty Corporation do?
- XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.
- Where are XOMA Royalty Corporation and DSUVIA based?
- XOMA Royalty Corporation is based in Berkeley, California, United States. DSUVIA is based in Emeryville, California, United States.
- Who are the decision-makers at XOMA Royalty Corporation?
- Fundz holds 3 contacts at XOMA Royalty Corporation. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Branded Legacy, Inc. signs letter of intent to purchase Sycamore BioPharma, LLC, to strengthen its position in the BioTech industry (March 1, 2024)
- Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform (February 26, 2024)
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right (February 16, 2024)
- Petauri™ Acquires FORCE Communications (February 14, 2024)
- Novo Holdings to Acquire Catalent (February 5, 2024)
- Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio (January 23, 2024)
Who to call at XOMA Royalty Corporation, and when
When XOMA Royalty Corporation changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day XOMA Royalty Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at XOMA Royalty Corporation, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at XOMA Royalty Corporation. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment XOMA Royalty Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired DSUVIA?
DSUVIA was acquired by XOMA Royalty Corporation, based in Berkeley. The deal was reported on January 18, 2024. XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty Corporation is privately held and operates in Biotechnology.
When did XOMA Royalty Corporation acquire DSUVIA?
XOMA Royalty Corporation's acquisition of DSUVIA was reported on January 18, 2024. XOMA Corporation has expanded its commercial royalty and milestone portfolio with the acquisition of an economic interest in DSUVIA® (sufentanil sublingual tablet) from Talphera, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does DSUVIA do?
It is privately held, operating in Biotechnology, and is based in Emeryville.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.